Yan Lin-Hai, Mo Xian-Wei, Qin Yu-Zhou, Wang Cheng, Chen Zhi-Ning, Lin Yuan, Chen Jian-Si
Department of Gastrointestinal Surgery, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Department of Nutriology, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Int J Clin Exp Med. 2015 Oct 15;8(10):18413-9. eCollection 2015.
Gastrointestinal stromal tumors (GISTs) are responsive to sunitinib (the tyrosine kinase inhibitor), this agent is widely used in prevention relapse of GISTs and neo-adjuvant chemotherapy in GIST patients without operation opportunity. The use of these agents has both advantages and disadvantages. On the one hand, it can improve the outcome for patient. On the other hand, it may lead to consumptive hypothyroidism, a rare syndrome caused by increased catabolism of T4 and T3 by increased type 3 iodothyronine deiodinase (D3) activity. D3 is the major physiologic inactivator of thyroid hormone, this selenoenzyme catalyzes the inner-ring deiodination of T(4) to reverse T(3) and T(3) to 3, 3;-diiodothyronine, both of which are biologically inactive [1]. Increased monitoring and supernormal thyroid hormone supplementation are required for affected patient.
The aim of the study was to report the first case of consumptive hypothyroidism in an athyreotic patient after surgical resection of gastrointestinal stromal tumor.
DESIGN, SETTING, AND PATIENT: A 60-year-old athyreotic male was presented and he was euthyroid when receiving a stable therapeutic dose of thyroid hormone which was used to treat consumptive hypothyroidism resulting from the side effects of sunitinib, which is used for treatment of neo-adjuvant chemotherapy in gastrointestinal stromal tumor. With a discovery of large D3-expressing gastrointestinal stromal tumor, this patient suffered from marked Hyperthyrotropinemia, which instantly worsened after surgical resection of the gastrointestinal stromal tumor and then continued for 12 weeks after the surgical resection, in spite of further increases in levothyroxine therapy. The patient also had low serum T3 and elevated serum reverse T3 (rT3).
The patient's consumptive hypothyroidism caused by marked overexpression of the thyroid hormone-inactivating D3 within the gastrointestinal stromal tumor and adjacent normal gastrointestinal tissue.
D3 immunostaining of the patient's gastrointestinal stromal tumor was positive, with no significant immunoreactivity in adjacent normal gastrointestinal tissue. The expression levels of CD34, CD117, and DOG1 in peri-tumor tissue samples was lower than that in tumor tissue. The mRNA expression level of KIT exon17 in peri-tumor tissue was higher than that in tumor tissue.
This is the first case report of consumptive hypothyroidism in an adult after surgical partial resection of the gastrointestinal stromal tumor. This case demonstrates that hyperthyrotropinemia may worsen after surgical resection of the gastrointestinal stromal tumor.
胃肠道间质瘤(GISTs)对舒尼替尼(一种酪氨酸激酶抑制剂)有反应,该药物广泛用于预防GISTs复发以及用于没有手术机会的GIST患者的新辅助化疗。这些药物的使用有其利弊。一方面,它可以改善患者的预后。另一方面,它可能导致消耗性甲状腺功能减退,这是一种罕见的综合征,由3型碘甲状腺原氨酸脱碘酶(D3)活性增加导致T4和T3分解代谢增加引起。D3是甲状腺激素的主要生理性失活剂,这种含硒酶催化T(4)内环脱碘生成反式T(3)以及T(3)生成3,3'-二碘甲状腺原氨酸,这两种产物均无生物活性[1]。对于受影响的患者,需要加强监测并补充超生理剂量的甲状腺激素。
本研究旨在报告首例胃肠道间质瘤手术切除后无甲状腺患者发生消耗性甲状腺功能减退的病例。
设计、地点和患者:一名60岁的无甲状腺男性患者,在接受稳定治疗剂量的甲状腺激素治疗因舒尼替尼副作用导致的消耗性甲状腺功能减退时甲状腺功能正常,舒尼替尼用于胃肠道间质瘤的新辅助化疗。发现一个表达大量D3的胃肠道间质瘤后,该患者出现明显的促甲状腺激素血症,在胃肠道间质瘤手术切除后立即恶化,并在手术切除后持续12周,尽管左甲状腺素治疗剂量进一步增加。患者还出现血清T3降低和血清反式T3(rT3)升高。
患者的消耗性甲状腺功能减退是由胃肠道间质瘤及相邻正常胃肠道组织中甲状腺激素失活剂D3的明显过表达引起的。
患者胃肠道间质瘤的D3免疫染色呈阳性,相邻正常胃肠道组织无明显免疫反应性。肿瘤周围组织样本中CD34、CD117和DOG1的表达水平低于肿瘤组织。肿瘤周围组织中KIT外显子17的mRNA表达水平高于肿瘤组织。
这是首例胃肠道间质瘤部分手术切除后成年患者发生消耗性甲状腺功能减退的病例报告。该病例表明胃肠道间质瘤手术切除后促甲状腺激素血症可能会恶化。